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Background: The purpose of this experimental study was to compare the immunohistochemical expression of 
SOX2 and BCL-2 in Odontogenic Keratocyst (OKC) and Ameloblastoma (AB) specimens, and to identify a pos-
sible correlation in their expression.
Material and Methods: Immunohistochemical analysis was performed to evaluate SOX2 and BCL-2 expression 
in OKC (n = 20) and AB (n = 20). The immunoexpression was analyzed by a quantitative and qualitative scoring 
system. The comparison between the immunoexpression of SOX 2 and BCL-2 was assessed by the Mann-Whitney 
U-test. Spearman’s correlation coefficient evaluated the correlation between SOX2 and BCL-2 expressions.
Results: SOX2 and BCL-2 expression was observed in all specimens of OKC in the full thickness of the epitheli-
um lining. SOX2 immunostaining was higher in OKC, in comparison with AB samples (P<0.05). BCL-2 immu-
nostaining between OKC and AB was not statistically significant. There was no significant correlation between 
SOX2 and BCL-2 in OKC and AB specimens.
Conclusions: SOX2 and BCL-2 expressions in OKC may suggest their relationship with the biological behavior 
of this lesion, and the higher expression of SOX2 might be an upstream influence on the Hh signaling pathway.
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Introduction
Odontogenic keratocyst (OKC) is a benign intraosse-
ous lesion of the jaws, and is of odontogenic origin, 
representing about 11.7% of odontogenic cysts (1). Over 
the last decades, the nature of odontogenic keratocysts 
(OKC) has been widely discussed (2). Most of the re-
cent debate has focused on their aggressive behavior 
and high recurrence rate, as well as the existence of 
molecular alterations in the OKC. These alterations are 
regarded as an important factor supporting their clas-
sification as a benign cystic neoplasm (3). OKCs pres-
ent significant changes in PTCH1 and in the Hedgehog 
(Hh) signaling pathway, and are one of the major molec-
ular alterations found in OKC lesions (4). Although the 
molecular changes were indeed observed in the OKC 
specimens, it seems that they are not exclusive to this 
condition, since similar molecular alterations have also 
been found in developmental cysts (5). This finding, to-
gether with the fact that some OKC lesions respond to 
marsupialization procedures, puts their neoplastic na-
ture into question (6).
Ameloblastoma (AB) is a benign tumor of the odon-
togenic epithelium, and also has a recognized aggres-
sive nature, significant growth potential and a high 
recurrence rate (7). Many studies have attempted to 
investigate the AB gene expression profile (8-12); and 
some have suggested that the AB oncogenic transfor-
mation is related to abnormalities in multiple genes 
(11,12). Moreover, several of these investigations have 
proposed to compare the molecular characteristics of 
OKC and AB with the intent of understanding their 
biological behavior and development mechanisms 
(9,12). Apparently, they seem to be distinct lesions 
with respect to gene expression, in that AB presents 
a dental profile, expressing PITX2, MSX2, DLX1, 2, 
3, 4, ISL1, TBX1, IRX1, RUNX1 and SOX9, whereas 
KOCT presents an embryonic oral epithelium profile, 
expressing SOX2 (9). However, OKC and AB can also 
present some molecular similarities regarding altera-
tions in Hh (8,12,13), mitogen-activated protein kinase 
(MAPK)(14) and WNT/B-catenin signaling pathways 
(10,11,15).
In a previous study, it was found that OKCs present a 
high level of SOX2 expression, indicating that OKC 
epithelium could harbor a great number of cells with 
stem cell characteristics (9). SOX2 is a transcription 
factor expressed in embryonic and adult stem cells, and 
exerts an important influence on maintaining pluripo-
tency (16). It has been found to be related to oncogenic 
signaling pathways, controlling tumor cells by affect-
ing their fate, proliferation and apoptosis (17). In oral 
primitive epithelium SOX2 is highly expressed, and 
this expression is also sustained during tooth develop-
ment (9). SOX2 is not expressed in the epithelial rest 
cells of Malassez nor in the epithelial cells of Hertwig’s 
epithelial root sheath, but it is significantly expressed in 
dental lamina (16), which could probably be the source 
of OKC development (4). OKC also has an increased 
expression of BCL-2 (13,18), which is an anti-apoptotic 
gene with important implications in tumorigenesis and 
tumor progression (19). There is evidence that there ex-
ists some kind of interaction between SOX2 and BCL-2 
(20), inasmuch as both genes are related to Hh (13,21), 
MAPK (22) and WNT/B-catenin (16) signaling path-
ways. In fact, SOX2 plays a role in activating the Hh 
pathway, being responsible for sustaining the stem cell 
phenotype (21), and also has an effect on cell death pre-
vention by influencing BCL-2 levels (20).
Recently, Juuri et al. (2013) (16) showed that SOX2 is 
also expressed in AB and in fragments of dental lamina 
associated with the developing third molar, which could 
be a sign that this tissue may give rise to an AB. Ac-
cording to the mentioned study, SOX2 positive odon-
togenic epithelium may originate AB in this particular 
anatomic region, because SOX2 positive epithelium ap-
parently preserves the capacity to proliferate and pro-
duce dental epithelium.
Since SOX2 and BCL-2 could affect signaling pathways 
known to exert some sort of influence on OKC and AB, 
and since these two genes may interact with each other 
in other tumor models, the study of their expression in 
OKC and AB seems to be opportune. The understand-
ing of the OKC and AB genetic profile could be benefi-
cial to the elucidation of their pathogenesis and also to 
the proposal of new treatment modalities (4). Accord-
ingly, the aims of the present study were to compare the 
immunohistochemical expression of SOX2 and BCL-2 
in OKC and AB specimens, and to identify a possible 
correlation in their expression.
Material and Methods
- Study design and specimens
This experimental study included an immunohisto-
chemical analysis of SOX2 and BCL-2 proteins in for-
malin-fixed and paraffin-embedded tissue specimens of 
OKC (n= 20) and multicystic AB (n= 20), collected from 
the Laboratory of Oral Pathology of the Federal Univer-
sity of Goiás, during the period of 2011 and 2017. Only 
cases with sufficient tissue and with the description of 
clinical characteristics were included. Symptomatic 
cases or cases associated with clear signs of second-
ary infection were not included. The clinicopathologic 
features of the cases evaluated are depicted in Table 1. 
All samples were submitted to 5-μm histologic sections 
and routine staining with hematoxylin and eosin, and 
then analyzed by an oral pathologist, under light mi-
croscopy, to confirm their histopathological diagnosis. 
The OKC and multicystic AB samples were taken from 
40 patients with a mean age of 19.5 and 53.1 years old, 
respectively, and a female to male ratio of 2:1.
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dase was consumed with 6% hydrogen peroxide and an 
absolute methanol solution in two baths of 15 min each 
at room temperature. After washing in TRIS buffer (pH 
7.6), the slides were incubated with primary anti-SOX2 
(dilution 1:50) and anti-BCL-2 (dilution 1:50) antibod-
ies for 30 minutes.  The slides were then exposed to an 
avidin–biotin complex (LSAB-Kit + HRP; Dako Cyto-
mation, Carpinteria, CA, USA) and to 3,3′-diaminoben-
zidin chromogen (DAB+; Dako Cytomation, Carpinte-
ria, CA, USA), and subsequently counterstained using 
Meyer’s hematoxylin, dehydrated in ethanol, cleared 
in xylene and cover-slipped. Sections of adenoid cystic 
- Immunohistochemistry
The immunohistochemical reactions for anti-SOX2 
(mouse monoclonal antibody, ref: sc365823; Santa 
Cruz Biotechnology, Santa Cruz, CA) and anti-BCL-2 
(mouse monoclonal antibody, clone 124; Dako Cytoma-
tion, Glostrup, Denmark) were performed using 3-μm 
4% formalin-fixed slides submitted to dewaxing with 
xylene and hydration, in a series of decreasing concen-
trations of ethanol. Antigen retrieval was performed by 
immersing the sections in 10 mM monohydrated citrate 
buffer solution (pH 6.0), and then heating them in a mi-
crowave oven for 15 minutes. The endogenous peroxi-
Case Gender Age Anatomical site Histopatological diagnosis
1 F 35 Right posterior mandible Odontogenic Keratocyst
2 M 65 Anterior maxilla Odontogenic Keratocyst
3 M 15 Maxillary sinus Odontogenic Keratocyst
4 M 38 Left posterior mandible Odontogenic Keratocyst
5 M 51 Right posterior mandible Odontogenic Keratocyst
6 M 27 Right posterior mandible Odontogenic Keratocyst
7 M 31 Left posterior mandible Odontogenic Keratocyst
8 F 21 Left posterior mandible Odontogenic Keratocyst
9 M 10 Right posterior maxilla Odontogenic Keratocyst
10 F 34 Left posterior mandible Odontogenic Keratocyst
11 F 32 Maxillary sinus Odontogenic Keratocyst
12 F 19 Left posterior mandible Odontogenic Keratocyst
13 M 44 Anterior mandible Odontogenic Keratocyst
14 M 65 Right posterior mandible Odontogenic Keratocyst
15 M 65 Right posterior mandible Odontogenic Keratocyst
16 F 27 Maxillary sinus Odontogenic Keratocyst
17 M 26 Left posterior mandible Odontogenic Keratocyst
18 F 16 Anterior mandible Odontogenic Keratocyst
19 F 36 Right posterior maxilla Odontogenic Keratocyst
20 M 8 Anterior mandible Odontogenic Keratocyst
21 F 22 Left posterior mandible Ameloblastoma
22 F 30 Right posterior mandible Ameloblastoma
23 F 42 Right posterior mandible Ameloblastoma
24 M 56 Right posterior mandible Ameloblastoma
25 M 40 Left posterior mandible Ameloblastoma
26 F 14 Left posterior mandible Ameloblastoma
27 M 22 Anterior mandible Ameloblastoma
28 F 46 Right posterior mandible Ameloblastoma
29 M 25 Left posterior mandible Ameloblastoma
30 F 17 Right posterior mandible Ameloblastoma
31 F 43 Left posterior mandible Ameloblastoma
32 F 29 Anterior mandible Ameloblastoma
33 M 14 Left posterior mandible Ameloblastoma
34 F 42 Left posterior mandible Ameloblastoma
35 F 30 Left posterior mandible Ameloblastoma
36 F 25 Left posterior mandible Ameloblastoma
37 F 26 Right posterior mandible Ameloblastoma
38 M 21 Right posterior mandible Ameloblastoma
39 M 32 Left posterior mandible Ameloblastoma
40 F 38 Anterior mandible Ameloblastoma
Table 1:  Clinical and pathological characteristics of the Odontogenic Keratocyst and Ameloblastoma.
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carcinoma were used as a positive control for SOX2, 
whereas lymph node with follicular hyperplasia was 
used for BCL-2. The negative control was obtained 
by omitting the primary antibody during the reaction. 
The sections were considered positive for SOX2 when 
brown staining was observed in the cell nucleus, and 
positive for BCL-2 when staining was localized in the 
cytoplasmic compartment. The histological slides were 
digitalized under 200x magnification and the immuno-
histochemical expressions were analyzed using ImageJ 
computer software (NIH, Bethesda, MD, USA).
The SOX2 and BCL-2 immunoexpression was analyzed 
by a quantitative and qualitative scoring system based 
on the percentage of staining cells and the intensity of 
this staining.  This scoring system designates 3 cat-
egories to evaluate the proportion of positive cells (0, 
no expression; 1, expression in <50% of cells; and 2, 
expression in >50% of cells), and another 3 categories 
to estimate staining intensity (0, no staining; 1, weak; 
and 2, strong). The percentage of positive cells and the 
staining intensity in the OKC epithelium were analyzed 
in basal and suprabasal layers separately. In AB speci-
mens, the expression of SOX2 and BCL-2 were evalu-
ated individually in central areas of neoplastic epithe-
lium and in peripheral ameloblast-like columnar cells. 
The final score for SOX2 and BCL-2 was calculated as 
follows: the sum of the basal and suprabasal ratio values 
multiplied by the highest intensity value found in the 
OKC specimen. In AB, the final scores were also ar-
rived at by adding the proportional values of the two 
different regions of the neoplastic epithelium (center 
and peripheral cells), multiplied by the highest intensity 
value found in the AB specimen. This system generated 
a score ranging from 0 to 8. The immunoexpression of 
the mentioned markers was evaluated at “hot spots” by 
two independent pathologists, blinded to all other infor-
mation on the cases.
- Statistical analysis
The statistical analysis was performed with SPSS 
20.0 software (Statistical Package for Social Sciences, 
Chicago, IL, USA). The comparison between the im-
munoexpression of SOX2 and BCL-2 in OKC and AB 
specimens was submitted to the Mann–Whitney U-test. 
Spearman’s correlation coefficient was performed to 
evaluate the correlation between SOX2 and BCL-2 ex-
pression. Statistical significance was set at P<0.05.
Results
- SOX2 expression in odontogenic keratocyst and am-
eloblastoma
SOX2 immunostaining was observed in all the samples 
of OKC (n=20) (Table 2), with patent expression in the 
nucleus of basal and suprabasal cells of the epithelium 
lining (Fig. 1). A stronger expression of SOX2 was ob-
served in the basal layer of OKC (Fig. 1). In multicys-
tic AB, SOX2 expression was found in 55% (n=11) of 
the sample (Table 2), with a weak nuclear expression of 
SOX2 in the central areas of the neoplastic epithelium 
nests (Fig. 1), especially in areas resembling stellate re-
ticulum (Fig. 1).
Fig. 1: Immunohistochemical expression of SOX2 in odontogenic 
keratocyst (OKC) and ameloblastoma (AB) histological specimens. 
(A) SOX2 nuclear expression in palisade basal cell layer (arrow 
heads) of OKC (100x). (B) SOX2 nuclear expression in entire thick-
ness of OKC epithelium lining (200x). (C) SOX2 shows weak nuclear 
expression in central areas of neoplastic epithelium nests of AB (as-
terisk) (100x). (D) Weak expression of SOX2 in areas resembling 
stellate reticulum (arrow heads), and discrete staining in peripheral 
ameloblast-like columnar cells of neoplastic epithelium (200x).
Score
OKC (n=20) ABa (n=20)
P
n % n %
0 - 0.0 9 45.0
1 - 0.0 9 45.0
2 - 0.0 2 10.0 < 0.001
3 1 5.0 - 0.0
6 10 50.0 - 0.0
8 9 45.0 - 0.0
a Mann–Whitney U-test
Table 2:  SOX2 final scores for odontogenic keratocyst (OKC) and multicystic ameloblastoma (AB).
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To a lesser extent, a discrete SOX2 expression was also 
seen in the peripheral ameloblast-like columnar cells 
of the neoplastic epithelium (Fig. 1). In OKC, the final 
score for SOX2 ranged from 3 to 8, revealing the highest 
expression of this marker in OKC, in comparison with 
AB samples (Mann–Whitney U-test, P<0.05) (Table 2).
- BCL-2 expression in odontogenic keratocyst and am-
eloblastoma
BCL-2 expression was observed in 100% (n=20) of the 
OKC specimens (Table 3), showing a marked cytoplas-
mic BCL-2 expression in cells of the basal layer of the 
odontogenic epithelium lining (Fig. 2). Cytoplasmic 
expression of BCL-2 was also noted in 85% (n=17) of 
multicystic AB samples (Table 3), with an evident ex-
pression in both the central and peripheral regions of 
neoplastic odontogenic epithelium nests (Fig. 2). There 
was no significant difference in the BCL-2 immunos-
taining between OKC and AB, considering that their 
final score ranged from 1 to 6 (Table 3).
- Correlation of SOX2 and BCL-2 expression 
SOX2 and BCL-2 showed no significant correlation in 
either OKC (r = -0.5111x; P=0.136) or multicystic AB 
specimens (r = -0.7018x; P=0.461).
Discussion
Previous WHO classification of head and neck tumors 
have aroused extensive discussion around the nature of 
OKCs (3). In 2005, the WHO consensus group reclassi-
fied OKC as a benign odontogenic tumor derived from 
the odontogenic epithelium. This classification was 
based on the growth potential, the putatively high recur-
rence rate, and the presence of mutations in OKC speci-
mens (3). However, since these lesions could regress 
following decompression procedures, and could also 
present molecular alterations that are more frequently 
observed in syndromic cases (nevoid basal cell carci-
noma syndrome), the WHO 2017 expert panel recog-
nized OKC as a developmental odontogenic cyst (23). It 
is believed that the lack of evidence supporting the neo-
plastic nature of OKC was taken into account in the last 
WHO classification, and the assumption that this lesion 
actually does not constitute a tumor was discussed (23). 
These issues reflect the ongoing studies on OKC molec-
ular characteristics, which have focused on expounding 
the reasons for its locally aggressive biological behavior 
and its continuous growth potential.
SOX2 and BCL-2 have a significant role in oncogenic 
signaling pathways, involved in cell proliferation and 
apoptosis (24), and their expression can be found in OKC 
(9,18). In the present study, we aimed to analyze the im-
munohistochemical expression of SOX2 and BCL-2 in 
OKC, and to identify a possible correlation in their ex-
pression. Additionally, since AB is a well-recognized, 
locally aggressive and recurrent odontogenic tumor, 
we also sought to compare its expression with the OKC 
expression. In this case, we found a greater expression 
of SOX2 in OKC than AB, with noticeable staining in 
all cell layers of the cyst lining. This high expression 
of SOX2 could denote that OKC cells have significant 
self-renewal and proliferative properties (16,25). This 
would suggest that there is an imbalance between cell 
growth and cell death in OKC, which could be a sign 
Score
OKC (n=20) ABa (n=20)
P
n % n %
0 - 0.0 3 15.0
1 1 5.0 1 5.0
2 9 45.0 - 0.0 0.391
3 - 0.0 1 5.0
6 4 20.0 7 35.0
8 6 30.0 8 40.0
a Mann–Whitney U-test
Fig. 2: Immunoexpression of BCL-2 in the epithelium lining of 
odontogenic keratocyst (OKC) and ameloblastoma (AB) specimens. 
(A) BCL-2 staining in palisade basal cell layer (arrow heads) of OKC 
(100x). (B) Cytoplasmic expression of BCL-2 in basal and parabasal 
cell layers of OKC (200X).  (C) BCL-2 staining in peripheral regions 
of neoplastic odontogenic epithelium nests (arrow heads) (100x). (D) 
Cytoplasmic expression of BCL-2 in central areas resembling stel-
late reticulum (asterisk) (200x).
Table 3:  SOX2 final scores for odontogenic keratocyst (OKC) and multicystic ameloblastoma (AB).
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of neoplastic behavior (26). In addition, SOX2 expres-
sion could also imply that a particular group of cells has 
stem cell properties, contributing to maintain clonoge-
nicity (27). The weak or absent expression of SOX2 in 
AB specimens found in the present study could imply 
that this particular odontogenic tumor presents another 
molecular pathway responsible for conserving its neo-
plastic behavior.
SOX2 overexpression is observed in different types of 
malignancies (28), including squamous cell lung carci-
nomas, squamous cell esophageal carcinomas (29), oral 
squamous cell carcinomas (30), melanoma, sinonasal 
carcinomas, Ewing’s sarcoma (28) and ameloblastic 
carcinoma (31). Despite the marked expression of SOX2 
in cancer, this protein is also expressed in the epithe-
lium of developing teeth (16), in the surface epithelium 
of oral mucosa and in the epithelium lining of dentiger-
ous cysts (31).
In the present study, SOX2 staining was noted in the en-
tire thickness of the OKC epithelium lining, which could 
imply that all cell layers of OKC specimens preserve 
progenitor characteristics of odontogenic epithelium, 
presenting a stem cell-like phenotype, and a continuous 
growth (32). This expression, in a very cautious conjec-
ture, could be interpreted as part of the physiological 
expression of SOX2 related to epithelium turnover, re-
stricted to cells of the stratified epithelium proliferation 
zone, more specifically those in the basal cell layer (33). 
However, in the present study, SOX2 staining was also 
found in the intermediate and surface cells, which po-
tentially indicates that the upper layer cells of the OKC 
epithelium lining also present a proliferative potential 
and stem cell properties (16,25).
Regarding this proliferative potential, the findings of a 
previous investigation with specific markers are consis-
tent with ours, namely the higher proliferative activity 
in the intermediate layers of OKC (33). According to 
Kichi et al. (33) (2005), the Ki-67-positive ratio ob-
served in the OKC epithelium lining was about 15% in 
the basal layer and close to 36% in the intermediate lay-
er. Their results, in association with the SOX2 expres-
sion observed in the present investigation, indicate that 
the intermediate cell layer of OKC possesses significant 
proliferative activity.
Understanding the pathogenesis and nature of OKC 
is important in order to clarify its aggressive nature, 
and also propose new treatment modalities (4). There 
are many molecular alterations related to sporadic and 
syndromic OKC cases, several of which could influ-
ence important cell signaling pathways (4,34). One 
of the main genetic changes described in OKC is the 
dysregulation of the hedgehog (Hh) signaling pathway 
caused by mutations in the Patched transmembrane 
spanning receptor 1 (PTCH1) (4). Hh is a central con-
troller in embryonic development organization, par-
ticipating in cell proliferation, cell fate determination, 
differentiation and stem cell maintenance (35). Hh 
hyperactivation is responsible for neoplastic transfor-
mation in different types of tumors (35), according to 
several modes of pathway activation described in the 
literature (36). One of the main Hh pathway activators 
is characterized by the binding of Hh to PTCH1 and 
consequent release of the smoothened (SMO) of the re-
pressive action of PTCH1 (36).  SMO thus participates 
in  activating Gli, which mediates the Hh target gene 
expression (13). In fact, Hh activity may include the 
expression of genes that affect proliferation, cell sur-
vival and angiogenesis (37).
The Hh downstream protein Gli1 can regulate BCL-2 
(37), an important anti-apoptotic gene, which encodes 
a protein capable of preventing apoptosis by enabling 
cell survival independently of cell division (38). In this 
study, we found a significant BCL-2 expression in OKC 
and AB. It was observed that the BCL-2 staining in 
OKC specimens was restricted to the cytoplasm of cells 
of the lower third of the epithelium lining.  Previous 
investigations have also shown that BCL-2 expression 
is increased in OKC in the basal layer cells (18). This 
BCL-2 expression could contribute to inhibit apoptosis 
in OKC cells, by allowing genetically unstable cells to 
survive and accumulate additional mutations that even-
tually lead to its neoplastic transformation (39). How-
ever, the single expression of BCL-2 is not enough to 
endorse the neoplastic nature of OKC, although it has 
been found to be significantly expressed in AB, a lesion 
with a recognized neoplastic nature.
Here we found that OKC expresses SOX2 and BCL-2 
proteins in a significant manner, but with no statistical 
correlation between them. Nevertheless, it is plausible 
to assume that their expression in OKC is not just a 
coincidence, since both are related to the Hh signaling 
pathway (35, 39,40) and both seem to be influenced by 
miR-15a (24,41). Our findings are in sync with those of 
other studies that also found SOX2 and BCL-2 expres-
sion in OKC (9,18). However, none of these investiga-
tions proposed to analyze the expression of these two 
markers together, or even made any consideration re-
garding their relationship. As mentioned before, Hh 
signaling pathway dysregulation is involved in anti-
apoptotic ability, enhanced proliferative capacity and 
maintaining the stemness of tumor cells (35). There 
is evidence that the anti-apoptotic action of BCL-2 is 
a downstream target of the Hh pathway (35), and acts 
to promote tumor cell survival. In addition, there is 
evidence that SOX2 is an upstream protein of the Hh 
signaling pathway, and acts to alter the cell prolifera-
tion potential and maintain the stemness of tumor cells 
(39). Diniz et al. (41) (2012) demonstrated the epigenetic 
mechanism (miRNAs) that might lead to the regulation 
of BCL-2 expression in OKC. According to their study, 
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miR-15a overexpression seems to downregulate BCL-2, 
acting as a suppressor of this apoptotic gene. Curiously, 
this influence of miR-15a in BCL-2 levels was also dem-
onstrated in colon cancer (24). In the study mentioned, 
the overexpression of miR-15a showed downstream 
suppression of BCL-2 and SOX2 proteins (24).
The significant expression of SOX2 and BCL-2 ob-
served in the present investigation with OKC specimens 
could offer a hint into their biological nature and patho-
genesis. Although the immunohistochemical expres-
sion of only two markers is insufficient to prove that 
OKC is a cystic tumor, our results suggest that SOX2 
and BCL-2 are related to the persistent growth potential 
of OKC, a characteristic compatible with its neoplastic 
nature. In summary, a higher expression of SOX2 was 
observed in OKC specimens in comparison with AB. 
BCL-2 was significantly expressed in OKC and AB. 
Although there was no statistical association between 
SOX2 and BCL-2, we believe that their expression 
could be related to the proliferative and anti-apoptotic 
capability of the OKC epithelium lining.  Therefore, we 
suggest that SOX2 and BCL-2 are somehow associated 
with the biological behavior of OKC, and that the higher 
expression of SOX2 found in the present study might 
be an upstream influence on the Hh signaling pathway.
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